All News

Yen et al. Taiwanese study of risk of MACE in SSc. No difference in MACE IRR 1.15 (95%CI 0.87–1.52) or stroke IRR 0.89 (95%CI 0.61-1.29), increase in MI IRR 1.76 (95%CI 1.08-2.86) @RheumNow #ACR22 Abstr#1191 https://t.co/3BiTLafGmk https://t.co/IManEvAh47

Links:

Richard Conway RichardPAConway ( View Tweet)
There's a lot of Scleroderma-like fibrosing skin disorders! #ACR22 @RheumNow #RheumTwitter @rheumarhyme https://t.co/W1AEtfeKZc
sheila RHEUMarampa ( View Tweet)
Scleredema has an indolent course Affected skin is doughy Has 3 clinical subgrps: 💠classic adultorum - self-limited, +visceral involvement 💠blood dyscrasia 💠diabetes - visceral involvement is rare #ACR22 @Rheumnow @rheumarhyme https://t.co/ZlQmCc1WYa
sheila RHEUMarampa ( View Tweet)
#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm

Links:

Richard Conway RichardPAConway ( View Tweet)
Dr. Wigley describes the edematous phase of early #scleroderma: ☝️ Friction rubs are a sign of active disease and assoc. with poor outcomes #ACR22 @RheumNow @rheumarhyme https://t.co/ooXYp1wXzu
sheila RHEUMarampa ( View Tweet)
☝️Remember: Not all skin thickening is SSc! 🔸Lipodermatosclerosis is a differential. Has an inverted champagne bottle appearance - caused by venous stasis and venous HTN #ACR22 @RheumNow #Scleroderma #RheumTwitter https://t.co/joWWn6BnVC
sheila RHEUMarampa ( View Tweet)
Add GPA to the list of causes of dacryoadenitis (inflammation of the lacrimal gland, main or accessory). Differential diagnoses of dacryoadenitis: ● Sjogren's ● Sarcoidosis ● IgG4 RD ● AL Amyloidosis ● GPA John Stone, Secrets and Pearls #ACR22 @RheumNow https://t.co/dvXbkpfcAq
Dr. Antoni Chan synovialjoints ( View Tweet)
Khanna @sclerodermaUM. SLS-III MMF+Pirfenidone vs MMF alone in SSc-ILD. Underpowered due to COVID (51 vs 150). No difference FVC 18 months ?more rapid improvement in combo. Better HRCT, PROs in combination. Need another study! @RheumNow #ACR22 Abstr#0520 https://t.co/K2Ne6PSHkS https://t.co/P6A7OJpzCf

Links:

Richard Conway RichardPAConway ( View Tweet)
Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests worse outcomes for Black patients relate to more severe disease at presentation rather than treatment failure @RheumNow #ACR22 Abstr#0521 https://t.co/xZtAt6Kw1f https://t.co/f0jG9jsgQ7

Links:

Richard Conway RichardPAConway ( View Tweet)
#ACR22 Yr in Review. John Varga says novel vaccination immune therapy may reverse #fibrosis - at least in mice. Hope for #scleroderma & other fibrotic diseases. Data need to be transferred into human experiments @RheumNow https://t.co/ybFRXheQq3
Janet Pope Janetbirdope ( View Tweet)
RheumNow Podcast square

ACR Award Winners (10.21.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

Read Article
Tofacitinib shows promise in scleroderma https://t.co/6qUGLlztBd https://t.co/Mk2x2HAkiO

Links:

Dr. John Cush RheumNow ( View Tweet)
PSS.scleroderma.arthritis.contractures

Tofacitinib shows promise in scleroderma

d EurekAlert!

Systemic sclerosis is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the U.S. With no licensed treatments available for this subset of scleroderma patients, rheumatology researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases.

Read Article
RheumNow Podcast square

RheumNow Podcast – “That’s Not My Name” (10.7.2022)

d Jack Cush, MD

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.

Read Article
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/PPAHocDWBj https://t.co/hZDGOF6r9k

Links:

Dr. John Cush RheumNow ( View Tweet)
Cancer Risk with Scleroderma Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer. https://t.co/2sCI6AejRn https://t.co/estX9D39tZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Cancer Risk with Scleroderma Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer. https://t.co/9w53NO3AsU https://t.co/bSkFhTN3v2

Links:

Dr. John Cush RheumNow ( View Tweet)
PSS.hands_.Raynauds.jpg (keep)

Cancer Risk with Scleroderma

d Jack Cush, MD

Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer.

The registry included 1930 patients with SSc and were compared to a matched general population to derive the standardized incidence ratios (SIRs) and independent cancer risk factors.

Read Article
I created an online version of the Modified Rodnan Skin Score (mRSS) to make it easier to calculate References mentioned below tool: https://t.co/5Us3usCTsC @SindhuJohnson5 @Janetbirdope #scleroderma #rheum #rheumatology

Links:

A Omar ahomar ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.